「aris」の検索結果

Check a prototype against its original design direction and requirements before shipping. Compares implementation to the mockup/spec/context, flags drift in layout, spacing, type, color, states, and behavior, and reports a pass/fix list. Use when the user says "design QA", "does it match the design", "check against the spec", "conformance check", or before sharing/handing off a prototype. Part of the Product Design set. Uses a browser tool for visual comparison.

日本語の概要は準備中です。原文の説明を表示しています。

Causal inference with treatment/control groups over time. Use when user mentions: treatment effects, policy evaluation, pre/post comparison, parallel trends, DID, DiD, difference in differences, natural experiment, quasi-experimental.

日本語の概要は準備中です。原文の説明を表示しています。

Close out a session — summarise what changed, capture what was learned, and prepare the commit.

日本語の概要は準備中です。原文の説明を表示しています。

Generate hand-drawn style diagrams and infographics for recovery education articles. Creates anatomist's notebook aesthetic visuals - brain diagrams, timelines, social comparisons, and process flows using continuous line art, semantic color coding, and margin annotations.

日本語の概要は準備中です。原文の説明を表示しています。

Benchmark multi-agent coordination systems with experiment design, power analysis, human rating protocols, bootstrap confidence intervals, and reproducible reporting. Use for salvage latency, recovery fidelity, coordination overhead, and protocol comparison studies. NOT for ML model benchmarking, web-product A/B testing, survey design, or general-purpose data science.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze hierarchical DAG-like systems by separating undirected substrate from ordering metadata, then classifying diamonds, mixers, shortcuts, and hidden cycle structure. Use for workflow architecture, citation or genealogy DAG comparison, and information-flow diagnosis. NOT for ordinary cycle detection in arbitrary graphs, one-node runtime debugging, or systems with no real ordering constraint.

日本語の概要は準備中です。原文の説明を表示しています。

Tracks cumulative LLM costs across DAG execution and makes real-time decisions to stay within budget. Downgrades models, skips optional nodes, or stops early when cost exceeds thresholds. Use when managing execution budgets, analyzing cost breakdowns, or optimizing model routing for cost. Activate on "cost budget", "too expensive", "reduce cost", "cost optimization", "model downgrade", "budget exceeded". NOT for LLM model selection logic (use llm-router), pricing comparisons across providers, or billing/invoicing.

日本語の概要は準備中です。原文の説明を表示しています。

Build and adopt production AI agent infrastructure in 2026. Covers framework selection (LangGraph, CrewAI, AutoGen, MCP), orchestration patterns, evaluation, observability, memory systems, and tool use. Also covers the SOCIAL dimension: how to sell agent infrastructure internally, change management, measuring ROI, building trust in autonomous systems, and scaling adoption across teams. Activate on: "agent infrastructure", "agent framework comparison", "which agent framework", "sell AI tools internally", "agent adoption", "agent observability", "agent evaluation", "MCP architecture", "agentic mesh", "enterprise AI agents", "AI change management", "agent ROI". NOT for: building specific agents (use ai-engineer), designing agent behavior patterns (use agentic-patterns), prompt tuning (use prompt-engineer).

日本語の概要は準備中です。原文の説明を表示しています。

Data structures and serialization formats for agent-to-agent communication. Covers message envelopes, structured output schemas, capability declarations, task handoff payloads, error/retry signaling, and context windows as data structures. Deep comparison of A2A protocol, MCP, OpenAI function calling, and LangChain message types. Teaches when to use rigid schemas vs free-form with validation, typed vs untyped, streaming vs batch. Activate on: "agent message format", "agent communication schema", "agent-to-agent protocol", "A2A protocol", "MCP message format", "structured output for agents", "agent interop", "interchange format", "agent serialization", "task handoff format", "capability declaration". NOT for: what agents say to each other (use agent-conversation-protocols), orchestration topology (use multi-agent-coordination), building agent infrastructure (use agentic-infrastructure-2026).

日本語の概要は準備中です。原文の説明を表示しています。

Detects m6A modifications from Oxford Nanopore direct-RNA-seq (DRS) signal using m6Anet (multiple-instance-learning over DRACH 5-mer signal). Covers the upstream pipeline (Dorado/Guppy basecalling -> minimap2 map-ont -> nanopolish eventalign -> m6anet dataprep -> m6anet inference), per-site vs per-read probability including the mod_ratio stoichiometry column, the DRACH-only constraint, minimum-coverage thresholds (20-50 reads/site), multi-condition comparison via xPore/Nanocompore/ELIGOS, Dorado native modification calling (RNA004, 2024+), and the cDNA-vs-DRS distinction (cDNA Nanopore CANNOT detect modifications). Use when calling m6A from ONT DRS without immunoprecipitation, choosing m6Anet vs xPore vs Nanocompore vs ELIGOS vs Dorado native, interpreting probability_modified vs mod_ratio vs per-read probabilities, deciding between m6Anet (known DRACH sites) and Dorado/Remora (genome-wide screening), pinning RNA002 vs RNA004 chemistry and basecaller versions, or troubleshooting eventalign/dataprep failures.

日本語の概要は準備中です。原文の説明を表示しています。

Visualises RNA-modification data with transcript-feature metagene plots (Guitar GuitarPlot; MetaPlotR; deepTools computeMatrix scale-regions), peak-centred heatmaps (ComplexHeatmap; deepTools plotHeatmap), IP-vs-input paired browser tracks (log2 IP/input bigWig via deepTools bamCompare; pyGenomeTracks; Gviz; IGV/UCSC track hubs), DRACH sequence-logo plots (ggseqlogo; MEME), feature-distribution stacked bars, and volcano/MA plots for differential modification. Establishes stop-codon enrichment in the metagene plot as the biological QC anchor for any MeRIP dataset (Dominissini 2012; Meyer 2012). Use when producing the canonical metagene plot with stop-codon enrichment as a QC anchor, building paired IP/input genome-browser tracks at single-locus resolution, plotting peak-centred heatmaps clustered by condition, summarising peak distribution across transcript features, generating DRACH motif logos as sanity checks, rendering volcano plots of differential m6A, or reproducing the stop-codon enrichment plot.

日本語の概要は準備中です。原文の説明を表示しています。

Add p-value brackets, significance asterisks, and effect-size annotations to distribution plots using ggpubr, ggsignif, and statannotations with correct test selection (parametric vs non-parametric vs paired), multiple-testing adjustment, and rendering of negative results. Use when a boxplot/violin/raincloud needs in-figure statistical comparisons between groups.

日本語の概要は準備中です。原文の説明を表示しています。

Build circular genome visualizations using circlize (R), pyCirclize (Python), or Circos (Perl CLI) with ideogram tracks, multi-data tracks (scatter, histogram, heatmap), chord/link arcs for interactions, and explicit circos.clear() between plots. Covers when circular is appropriate vs when Cartesian wins (Cleveland-McGill 1984), karyograms, and chromosome adjacency in chord diagrams. Use when adjacency on the circle conveys meaning — chromosome-level overview, structural variants, Hi-C interactions, cross-genome comparisons.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Build a differential-ready consensus peakset from per-replicate ATAC-seq peaks using iterative overlap removal, fixed-width re-centering, and majority-rule overlap. Use when generating a stable peak coordinate system for downstream differential accessibility, ML feature engineering, cross-sample comparison, or fixed-width peak counts; covers Corces 2018 iterative overlap (501 bp), DiffBind summit re-centering, and ENCODE consistency rules.

日本語の概要は準備中です。原文の説明を表示しています。

Plan, execute, and document validation, verification, and transfer of analytical procedures under the governing framework - ICH Q2(R2) and Q14, USP <1220>/<1225>/<1226>, ICH M10 bioanalytical, CLSI EP, or ISO/IEC 17025. Use for HPLC, LC-MS/MS, GC, CE, ICP-MS, dissolution, qNMR, qPCR, NIR, and ligand binding or cell-based assays whenever the question is whether a procedure is fit for its intended purpose. Triggers include "method validation", "analytical method validation", "AMV", "validation protocol", "acceptance criteria", "linearity", "reportable range", "accuracy and precision", "repeatability", "intermediate precision", "recovery", "LOD", "LOQ", "detection limit", "quantitation limit", "specificity", "robustness", "method transfer", "method comparison", "Deming", "Passing-Bablok", "Bland-Altman", "equivalence testing", "OOS investigation", "ICH Q2", "Q2(R2)", "Q14", "USP 1225", "ICH M10", "incurred sample reanalysis", "ISR", "CLSI EP", and any request to show that an assay works.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends re-evaluating the need for treatment of other pituitary hormone deficiencies in the postoperative period following surgical intervention for Cushing's syndrome. It is triggered when assessing a post-op CS patient for ongoing pituitary function, evaluating for hypopituitarism, or checking HPA axis recovery with morning cortisol/ACTH stimulation tests and pituitary MRI within 1–3 months.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends obtaining serum free T4 and prolactin levels within 1–2 weeks after transsphenoidal surgery (TSS) for Cushing's syndrome to screen for overt hypopituitarism. Use in postoperative Cushing's syndrome patients during the early recovery window when evaluating for new pituitary hormone deficiencies.

日本語の概要は準備中です。原文の説明を表示しています。

The Endocrine Society recommends a standard-dose corticotropin (ACTH) stimulation test to confirm primary adrenal insufficiency when clinical suspicion arises from symptoms such as hypotension, hyponatremia, hyperkalemia, or unexplained fatigue. Dosing is weight/age based: 250 µg for adults and children ≥2 years, 15 µg/kg for infants, and 125 µg for children <2 years.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends diagnostic testing to exclude primary adrenal insufficiency (PAI) in acutely ill patients presenting with otherwise unexplained volume depletion, hypotension, hyponatremia, hyperkalemia, fever, abdominal pain, hyperpigmentation, or hypoglycemia (especially in children). Use when clinical suspicion arises from these suggestive signs or symptoms suggestive of PAI.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests reducing the fludrocortisone dose in patients who develop new-onset hypertension while on fludrocortisone replacement for primary adrenal insufficiency. Consider dose reduction when hypertension arises alongside signs of mineralocorticoid excess such as edema, weight gain, or hypokalemia.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends adjusting glucocorticoid doses on the day of surgery based on illness severity and magnitude of surgical stress. Triggers when managing a patient requiring surgery needing perioperative glucocorticoid management, such as "patient on HC for central AI undergoing major abdominal surgery" or "patient with hypopituitarism scheduled for minor procedure".

日本語の概要は準備中です。原文の説明を表示しています。

Clarify requirements before implementing. Use when serious doubts arise.

日本語の概要は準備中です。原文の説明を表示しています。